• Publications
  • Influence
High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide
TLDR
Results demonstrate that BPI recognizes the highly conserved lipid A region of bacterial LPS via residues contained within the amino-terminal portion of the BPI molecule. Expand
Escherichia coli secretion of an active chimeric antibody fragment.
TLDR
The production in Escherichia coli of foreign heterodimeric protein reagents, such as Fab, should prove useful in the management of human disease. Expand
Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor
TLDR
BPI and an even more potent NH2-terminal fragment may protect against Gram-negative bacteria in the host by blocking bacterial proliferation as well as endotoxin-mediated effects, not only as components of the intracellular antibacterial arsenal of the neutrophil, but also as potentially therapeutic extracellular agents. Expand
Competition between rBPI23, a recombinant fragment of bactericidal/permeability-increasing protein, and lipopolysaccharide (LPS)-binding protein for binding to LPS and gram-negative bacteria
TLDR
It is demonstrated that rBPI23 binds more avidly to endotoxin than does rLBP and that, even in the presence of a 100-fold weight excess of rL BP, rB PI23 effectively blocks the proinflammatory response of peripheral blood mononuclear cells to endotoxemia. Expand
An amino-terminal fragment of human lipopolysaccharide-binding protein retains lipid A binding but not CD14-stimulatory activity.
TLDR
The results suggest that the structural features of LBP required for mediating LPS effects via CD14 are probably located in the C-terminal region of theprotein, suggesting these activities are mediated by structural elements residing in different regions of the protein. Expand
XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases
TLDR
It is reported here that XOMA 052 reduces acute inflammation in vivo, neutralizing the effect of exogenously administered human IL-1β and blocking peritonitis in a mouse model of acute gout. Expand
Secretion of functional antibody and Fab fragment from yeast cells.
TLDR
Yeast strains that secrete functional mouse-human chimeric antibody and its Fab fragment into the culture medium are constructed and chimeric whole antibody exhibited antibody-dependent cellular cytot toxicity activity but not complement-dependent cytotoxicity activity. Expand
Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2.
TLDR
Genetic engineering was used to obtain secretion of anti-human CD5 antibody fragments from Escherichia coli for conjugation to the 30-kDa form of ricin A chain (RTA30) and these immunoconjugates efficiently killed a CD5+ T-cell line and human peripheral blood T cells. Expand
Biochemical Characterization of Recombinant Fusions of Lipopolysaccharide Binding Protein and Bactericidal/Permeability-increasing Protein
TLDR
How closely related proteins such as BPI and LBP can have opposing effects on the body's response to LPS is defined by comparing the functional activities and pharmacokinetics of these fusions, the individual N-terminal domains, and the parent proteins. Expand
Monocyte tissue factor induction by lipopolysaccharide (LPS): dependence on LPS-binding protein and CD14, and inhibition by a recombinant fragment of bactericidal/permeability-increasing protein.
TLDR
Considering the involvement of LPS-induced TF in the potentially lethal intravascular coagulation in sepsis, inhibition of TF induction by rBPI23 may be of therapeutic benefit. Expand
...
1
2
3
4
5
...